Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses

Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, whi...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 78; no. 5; pp. 1307 - 1318
Main Authors Logan, Kirsty, Bahnson, Henry T., Ylescupidez, Alyssa, Beyer, Kirsten, Bellach, Johanna, Campbell, Dianne E., Craven, Joanna, Du Toit, George, Clare Mills, E. N., Perkin, Michael R., Roberts, Graham, Ree, Ronald, Lack, Gideon
Format Journal Article
LanguageEnglish
Published Denmark Blackwell Publishing Ltd 01.05.2023
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. Objective The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. Method As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. Results An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). Conclusion We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol
AbstractList An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol
The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias.BACKGROUNDThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias.The aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction.OBJECTIVEThe aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction.As part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.METHODAs part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.An intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).RESULTSAn intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.CONCLUSIONWe demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.
The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per-protocol (PP) analyses, which can be subject to bias. The aim of this study was to combine individual-level data from the LEAP and EAT trials and provide robust evidence on the bias-corrected, causal effect of early peanut introduction. As part of the European Union-funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. An intention-to-treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.
BackgroundThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias.ObjectiveThe aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction.MethodAs part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods.ResultsAn intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004).ConclusionWe demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.
BACKGROUND: The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. OBJECTIVE: The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. METHOD: As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. RESULTS: An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). CONCLUSION: We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction.
Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. Objective The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. Method As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. Results An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA (p < .0001) among children randomized to consume peanut from early infancy. A protective effect was present across all eczema severity groups, irrespective of enrollment sensitization to peanut, and across different ethnicities. Earlier age of introduction was associated with improved effectiveness of the intervention. In the pooled PP analysis, peanut consumption reduced the risk of PA by 98% (p < .0001). A causal inference analysis confirmed the strong PP effect (89% average treatment effect relative risk reduction p < .0001). A multivariable causal inference analysis approach estimated a large (100%) reduction in PA in children without eczema (p = .004). Conclusion We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier age of introduction. An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy prevents the development of peanut allergy regardless of presence or severity of eczema, ethnicity and sensitization to peanut. Earlier introduction of peanut before 6 months of age is more effective than later introduction in the prevention of peanut allergy. Causal inference methods accurately estimated the efficacy of this strategy while addressing the problems of poor adherence in the intention‐to‐treat analyses and biases in the per‐protocol analyses.Abbreviations: EAT, enquiring about tolerance; ITT, intention to treat; LEAP, learning early about allergy; PP, per protocol
Author Ylescupidez, Alyssa
Clare Mills, E. N.
Campbell, Dianne E.
Roberts, Graham
Perkin, Michael R.
Du Toit, George
Lack, Gideon
Beyer, Kirsten
Bellach, Johanna
Craven, Joanna
Bahnson, Henry T.
Logan, Kirsty
Ree, Ronald
AuthorAffiliation 5 School of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology University of Manchester Manchester UK
7 University of Southampton and Southampton NIHR Biomedical Research Centre Southampton UK
8 Departments of Experimental Immunology and of Otorhinolaryngology Amsterdam University Medical Centers Amsterdam Netherlands
6 The Population Health Research Institute St George's University of London London UK
1 Department of Women and Children's Health, School of Life Course and Population Sciences King's College London London UK
3 Charité Universitätsmedizin Berlin Berlin Germany
4 Children's Hospital at Westmead Westmead New South Wales Australia
2 Immune Tolerance Network Benaroya Research Institute Seattle Washington USA
AuthorAffiliation_xml – name: 6 The Population Health Research Institute St George's University of London London UK
– name: 3 Charité Universitätsmedizin Berlin Berlin Germany
– name: 5 School of Biological Sciences, Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology University of Manchester Manchester UK
– name: 8 Departments of Experimental Immunology and of Otorhinolaryngology Amsterdam University Medical Centers Amsterdam Netherlands
– name: 2 Immune Tolerance Network Benaroya Research Institute Seattle Washington USA
– name: 7 University of Southampton and Southampton NIHR Biomedical Research Centre Southampton UK
– name: 1 Department of Women and Children's Health, School of Life Course and Population Sciences King's College London London UK
– name: 4 Children's Hospital at Westmead Westmead New South Wales Australia
Author_xml – sequence: 1
  givenname: Kirsty
  surname: Logan
  fullname: Logan, Kirsty
  organization: King's College London
– sequence: 2
  givenname: Henry T.
  surname: Bahnson
  fullname: Bahnson, Henry T.
  organization: Benaroya Research Institute
– sequence: 3
  givenname: Alyssa
  surname: Ylescupidez
  fullname: Ylescupidez, Alyssa
  organization: Benaroya Research Institute
– sequence: 4
  givenname: Kirsten
  surname: Beyer
  fullname: Beyer, Kirsten
  organization: Charité Universitätsmedizin Berlin
– sequence: 5
  givenname: Johanna
  surname: Bellach
  fullname: Bellach, Johanna
  organization: Charité Universitätsmedizin Berlin
– sequence: 6
  givenname: Dianne E.
  surname: Campbell
  fullname: Campbell, Dianne E.
  organization: Children's Hospital at Westmead
– sequence: 7
  givenname: Joanna
  surname: Craven
  fullname: Craven, Joanna
  organization: King's College London
– sequence: 8
  givenname: George
  surname: Du Toit
  fullname: Du Toit, George
  organization: King's College London
– sequence: 9
  givenname: E. N.
  surname: Clare Mills
  fullname: Clare Mills, E. N.
  organization: University of Manchester
– sequence: 10
  givenname: Michael R.
  surname: Perkin
  fullname: Perkin, Michael R.
  organization: St George's University of London
– sequence: 11
  givenname: Graham
  orcidid: 0000-0003-2252-1248
  surname: Roberts
  fullname: Roberts, Graham
  organization: University of Southampton and Southampton NIHR Biomedical Research Centre
– sequence: 12
  givenname: Ronald
  surname: Ree
  fullname: Ree, Ronald
  organization: Amsterdam University Medical Centers
– sequence: 13
  givenname: Gideon
  orcidid: 0000-0001-7350-4021
  surname: Lack
  fullname: Lack, Gideon
  email: gideon.lack@kcl.ac.uk
  organization: King's College London
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36435990$$D View this record in MEDLINE/PubMed
BookMark eNqFkk1v1DAQhi1URLeFA38AWeJCD2n9lXV8QlXVQqWVuLRny3Emi4vXDnYCyr_H291FUBXhi-XxM69n_M4JOgoxAEJvKTmnZV0Y789pXSv5Ai0oV02llKqP0IJQUlei5s0xOsn5gRAimSKv0DFfCl4rRRYoXJvkZ-zCmGI32dHFgGOPBzBhGnGCEoN8OJZ3IK1nbGyKOePk8je8TnEachHAQ4weOmxCh62ZsvEl2EOCYKEEjZ8z5NfoZW98hjf7_RTd31zfXX2uVl8-3V5driorpJSVIXzZqQY44ZRTBVwQZhte875tGQjBDKGqEaJtemqAsLYFULBs5dIa1QrOT9HHne4wtRvoLJT-jNdDchuTZh2N03_fBPdVr-MPTQkjjLK6KHzYK6T4fYI86o3LFrw3AeKUNWu4YFRwSf6PSkFqwqUUBX3_BH2IUyqfsxUkUjaKSVqod39W_7vsg20FuNgBj0Yk6LV1o9maV5pxvnSht4Ohi2H6cTBKxtmTjIPoc-xe_afzMP8b1Jer1S7jF_HQyGk
CitedBy_id crossref_primary_10_1016_j_jaip_2024_05_028
crossref_primary_10_1007_s15007_024_6250_0
crossref_primary_10_1111_all_15676
crossref_primary_10_1111_all_16025
crossref_primary_10_1111_all_16069
crossref_primary_10_1111_all_16429
crossref_primary_10_1001_jamapediatrics_2023_0142
crossref_primary_10_3389_falgy_2025_1562667
crossref_primary_10_1097_ACI_0000000000000983
crossref_primary_10_3389_fsci_2024_1279192
crossref_primary_10_1016_j_jaci_2023_11_918
crossref_primary_10_1111_apa_16763
crossref_primary_10_29219_fnr_v68_10456
crossref_primary_10_1016_j_tjnut_2023_06_015
crossref_primary_10_1016_j_anai_2024_06_002
crossref_primary_10_1007_s13671_024_00452_w
crossref_primary_10_1016_j_jaip_2024_06_022
crossref_primary_10_3389_falgy_2023_1219268
crossref_primary_10_3390_allergies5010005
crossref_primary_10_1016_j_anai_2023_05_031
crossref_primary_10_3390_allergies4040016
crossref_primary_10_4168_aair_2023_15_4_419
crossref_primary_10_1016_j_jaip_2023_10_013
crossref_primary_10_1111_cea_14454
crossref_primary_10_1111_cea_14452
crossref_primary_10_3389_falgy_2024_1439303
crossref_primary_10_1111_pai_14094
Cites_doi 10.1016/j.jaci.2008.08.039
10.1056/NEJMoa1514210
10.5694/mja2.12102
10.1016/j.jaci.2012.09.015
10.1016/j.jaci.2020.01.015
10.1016/S0140-6736(22)00687-0
10.1542/peds.106.S4.1274a
10.1016/j.jaip.2015.12.016
10.1016/j.jaci.2016.10.010
10.1016/j.jclinepi.2018.06.009
10.1016/j.jaci.2019.06.046
10.1016/j.jaci.2015.12.1322
10.1111/j.1541-0420.2005.00377.x
10.1016/j.jaci.2020.01.016
10.1001/jama.2016.12623
10.1056/NEJMsm1605385
10.1056/NEJMoa1414850
10.1016/j.jaci.2019.07.032
10.1136/bmj.319.7211.652
10.1111/all.13127
10.1111/pai.13496
10.1002/sim.1903
ContentType Journal Article
Copyright 2022 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
– notice: 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
– notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
7S9
L.6
5PM
DOI 10.1111/all.15597
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
AGRICOLA

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Logan et al
EISSN 1398-9995
EndPage 1318
ExternalDocumentID PMC10202125
36435990
10_1111_all_15597
ALL15597
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: National Institute of Allergy and Infectious Diseases
– fundername: Medical Research Council
– fundername: National Peanut Board
– fundername: The Davis Foundation
  funderid: 1152998
– fundername: European Union
– fundername: Food Allergy Research and Education
– fundername: National Institute for Health Research
– fundername: Food Standards Agency
– fundername: Asthma UK
– fundername: Medical Research Council
  grantid: MC_G1001205
– fundername: NIAID NIH HHS
  grantid: UM1 AI109565
– fundername: NIAID NIH HHS
  grantid: HHSN272200800029C
– fundername: NIAID NIH HHS
  grantid: N01AI15416
– fundername: ;
– fundername: The Davis Foundation
  grantid: 1152998
GroupedDBID .3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
2WC
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TR2
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c4777-a036d98e3031319e3402c8353fbb2e442a019844b8f1ae02bbee9e6b76ca9b433
IEDL.DBID DR2
ISSN 0105-4538
1398-9995
IngestDate Thu Aug 21 18:36:47 EDT 2025
Fri Jul 11 18:27:40 EDT 2025
Fri Jul 11 10:11:30 EDT 2025
Sat Jul 19 05:42:19 EDT 2025
Wed Feb 19 02:23:43 EST 2025
Tue Jul 01 02:54:30 EDT 2025
Thu Apr 24 22:57:04 EDT 2025
Wed Jan 22 16:21:36 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords causal inference analysis
early introduction
peanut allergy prevention
Language English
License Attribution
2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4777-a036d98e3031319e3402c8353fbb2e442a019844b8f1ae02bbee9e6b76ca9b433
Notes Kirsty Logan and Henry T. Bahnson contributed equally to this manuscript.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0003-2252-1248
0000-0001-7350-4021
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15597
PMID 36435990
PQID 2807789271
PQPubID 34098
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10202125
proquest_miscellaneous_2834214370
proquest_miscellaneous_2740503774
proquest_journals_2807789271
pubmed_primary_36435990
crossref_citationtrail_10_1111_all_15597
crossref_primary_10_1111_all_15597
wiley_primary_10_1111_all_15597_ALL15597
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2023
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Zurich
– name: Hoboken
PublicationTitle Allergy (Copenhagen)
PublicationTitleAlternate Allergy
PublicationYear 2023
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 2004; 23
2018; 103
1998
2004
2020; 145
2005; 61
2008; 122
2019; 144
2017; 139
2022; 399
2015; 372
2016; 4
2017; 72
2021; 32
2021
2016; 316
2000; 106
2017; 77
2016; 374
2016
2016; 137
2014
2013; 131
1999; 319
2019; 210
e_1_2_9_11_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_12_1
SAS Institute Inc (e_1_2_9_18_1) 2016
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_20_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
Wooldridge JM (e_1_2_9_17_1) 2004
e_1_2_9_2_1
Committee on Toxicity of Chemicals in Food CpatE, Department of Health (e_1_2_9_3_1) 1998
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
References_xml – volume: 399
  start-page: 2398
  issue: 10344
  year: 2022
  end-page: 2411
  article-title: Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster‐randomised trial
  publication-title: Lancet
– volume: 77
  start-page: 1391
  issue: 14
  year: 2017
  end-page: 1398
  article-title: Per‐protocol analyses of pragmatic trials
  publication-title: N Engl J Med
– volume: 319
  start-page: 652
  year: 1999
  end-page: 653
  article-title: Can it work? Does it work? Is it worth it?
  publication-title: BMJ
– year: 2021
– volume: 316
  start-page: 1181
  issue: 11
  year: 2016
  end-page: 1192
  article-title: Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease. A systematic review and meta‐analysis
  publication-title: JAMA
– volume: 137
  start-page: 1477
  issue: 5
  year: 2016
  end-page: 1486
  article-title: Enquiring about tolerance (EAT) study: feasibility of an early allergenic food introduction regimen
  publication-title: J Allergy Clin Immunol
– volume: 144
  start-page: 1595
  issue: 6
  year: 2019
  end-page: 1605
  article-title: Factors influencing adherence in a trial of early introduction of allergenic food
  publication-title: J Allergy Clin Immunol
– year: 2016
– volume: 374
  start-page: 1733
  issue: 18
  year: 2016
  end-page: 1743
  article-title: Randomized trial of introduction of allergenic foods in breast‐fed infants
  publication-title: N Engl J Med
– volume: 61
  start-page: 962
  year: 2005
  end-page: 973
  article-title: Doubly robust estimation in missing data and causal inference models
  publication-title: Biometrics
– volume: 106
  start-page: 1274
  issue: 5
  year: 2000
  article-title: American Academy of Pediatrics recommendations for complementary feeding
  publication-title: Pediatrics
– year: 1998
– volume: 139
  start-page: 29
  issue: 1
  year: 2017
  end-page: 44
  article-title: Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel
  publication-title: J Allergy Clin Immunol
– volume: 372
  start-page: 803
  issue: 9
  year: 2015
  end-page: 813
  article-title: Randomized trial of peanut consumption in infants at risk for peanut allergy
  publication-title: N Engl J Med
– start-page: 2
  year: 2014
– volume: 210
  start-page: 89
  issue: 2
  year: 2019
  end-page: 93
  article-title: The Australasian Society of Clinical Immunology and Allergy infant feeding for allergy prevention guidelines
  publication-title: Med J Aust
– volume: 72
  start-page: 1267
  issue: 8
  year: 2017
  end-page: 1271
  article-title: Letter of response to Greenhawt et al. 'LEAPing through the looking glass: secondary analysis of the effect of skin test size and age of introduction on peanut tolerance after early peanut introduction'
  publication-title: Allergy
– volume: 131
  start-page: 135
  issue: 1
  year: 2013
  end-page: 143
  article-title: Identifying infants at high risk of peanut allergy: the learning early about peanut allergy (LEAP) screening study
  publication-title: J Allergy Clin Immunol
– volume: 23
  start-page: 2937
  year: 2004
  end-page: 2960
  article-title: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
  publication-title: Stat Med
– year: 2004
– volume: 103
  start-page: 10
  year: 2018
  end-page: 21
  article-title: Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials
  publication-title: J Clin Epidemiol
– volume: 144
  start-page: 1327
  issue: 5
  year: 2019
  end-page: 1335
  article-title: Earlier ingestion of peanut after changes to infant feeding guidelines: the EarlyNuts study
  publication-title: J Allergy Clin Immunol
– volume: 145
  start-page: 1305
  issue: 4
  year: 2020
  article-title: Low‐risk infants may still benefit from allergenic food consumption
  publication-title: J Allergy Clin Immunol
– volume: 32
  start-page: 843
  issue: 5
  year: 2021
  end-page: 858
  article-title: European academy of allergy and clinical immunology food allergy and anaphylaxis guidelines group. EAACI guideline: preventing the development of food allergy in infants and young children (2020 update)
  publication-title: Pediatr Allergy Immunol
– volume: 145
  start-page: 1305
  issue: 4
  year: 2020
  end-page: 1306
  article-title: Letter of response to Iglesia et al. “Low‐risk infants may still benefit from allergenic food consumption”
  publication-title: J Allergy Clin Immunol
– volume: 122
  start-page: 984
  issue: 5
  year: 2008
  end-page: 991
  article-title: Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy
  publication-title: J Allergy Clin Immunol
– volume: 4
  start-page: 221
  issue: 2
  year: 2016
  end-page: 225
  article-title: The complexities of early Peanut introduction for the practicing allergist
  publication-title: J Allergy Clin Immunol Pract
– ident: e_1_2_9_5_1
  doi: 10.1016/j.jaci.2008.08.039
– ident: e_1_2_9_7_1
  doi: 10.1056/NEJMoa1514210
– ident: e_1_2_9_26_1
  doi: 10.5694/mja2.12102
– ident: e_1_2_9_13_1
  doi: 10.1016/j.jaci.2012.09.015
– volume-title: Econometric Analysis of Cross Section and Panel Data
  year: 2004
  ident: e_1_2_9_17_1
– ident: e_1_2_9_23_1
  doi: 10.1016/j.jaci.2020.01.015
– ident: e_1_2_9_20_1
  doi: 10.1016/S0140-6736(22)00687-0
– ident: e_1_2_9_4_1
  doi: 10.1542/peds.106.S4.1274a
– ident: e_1_2_9_19_1
– ident: e_1_2_9_27_1
  doi: 10.1016/j.jaip.2015.12.016
– volume-title: COT Consumer Products and the Environment–Peanut Allergy. DoH
  year: 1998
  ident: e_1_2_9_3_1
– ident: e_1_2_9_10_1
  doi: 10.1016/j.jaci.2016.10.010
– volume-title: SAS/STAT 14.2 User's Guide
  year: 2016
  ident: e_1_2_9_18_1
– ident: e_1_2_9_21_1
– ident: e_1_2_9_11_1
  doi: 10.1016/j.jclinepi.2018.06.009
– ident: e_1_2_9_9_1
  doi: 10.1016/j.jaci.2019.06.046
– ident: e_1_2_9_14_1
  doi: 10.1016/j.jaci.2015.12.1322
– ident: e_1_2_9_15_1
  doi: 10.1111/j.1541-0420.2005.00377.x
– ident: e_1_2_9_22_1
  doi: 10.1016/j.jaci.2020.01.016
– ident: e_1_2_9_8_1
  doi: 10.1001/jama.2016.12623
– ident: e_1_2_9_12_1
  doi: 10.1056/NEJMsm1605385
– ident: e_1_2_9_6_1
  doi: 10.1056/NEJMoa1414850
– ident: e_1_2_9_25_1
  doi: 10.1016/j.jaci.2019.07.032
– ident: e_1_2_9_24_1
  doi: 10.1136/bmj.319.7211.652
– ident: e_1_2_9_28_1
  doi: 10.1111/all.13127
– ident: e_1_2_9_2_1
  doi: 10.1111/pai.13496
– ident: e_1_2_9_16_1
  doi: 10.1002/sim.1903
SSID ssj0007290
Score 2.5154672
Snippet Background The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA)....
The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the...
BackgroundThe Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA)....
BACKGROUND: The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA)....
An integrated meta‐analysis employing both LEAP (high risk) and EAT (normal risk) individual patient data shows that early introduction of peanut in infancy...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1307
SubjectTerms Allergens
Allergies
Arachis
causal inference analysis
Child
Children
Clinical trials
early introduction
Eczema
Food allergies
Humans
hypersensitivity
infancy
Infant
Original
ORIGINAL ARTICLES
patients
peanut allergy prevention
Peanut Hypersensitivity - epidemiology
Peanut Hypersensitivity - prevention & control
peanuts
Pediatrics
protective effect
relative risk
Risk Factors
Risk groups
risk reduction
Statistical analysis
Title Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.15597
https://www.ncbi.nlm.nih.gov/pubmed/36435990
https://www.proquest.com/docview/2807789271
https://www.proquest.com/docview/2740503774
https://www.proquest.com/docview/2834214370
https://pubmed.ncbi.nlm.nih.gov/PMC10202125
Volume 78
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb9QwEIdHpQfEhUfLI6VUpuqBS1ZJbK9jcaoQVYVahFAr9YAU2Y5DV6yyaLM5lL-eGedBl7YI9bZZzzpx4ln_Ys98BjjgVjqZT5M4LWmZEQV1rFHmxihOKsOVT01C-c6nn6fH5-LThbzYgPdDLkzHhxgn3Mgzwv81ObixzTUnN_P5hNbUKJOcYrVIEH39g45S_fwK6odYoFf3VCGK4hl_uT4W3RCYN-Mkr-vXMAAdPYFvw6V3cSc_Ju3KTtyvv6iO92zbU3jcC1N22PWkZ7Dh6y14eNovvW9DHVDIbEaR7WWHnGWLitFMfrtiSyLA-mY4pA1alt-vmAkNZxS_zkL-SIMVMNrWy5fM1CVzpm3wrLMh7RC_JEiKb57D-dHHsw_Hcb9ZQ-yEUio2OBSWOvecYJCp9hxfTB3KO15Zm3khMoNiMhfC5lVqfJJZ6732U6umzmgrOH8Bm_Wi9q-AlS4rpTJSEY1Opk5XWgudcIm1a5PbCN4Nj61wPcmcNtSYF8MbDbayCPcvgv3R9GeH77jNaHd49kXvwU1BlCCV60ylEbwdi9H3aEHF1H7Roo0ShNNBBf0Pm5yLDEWpSiJ42XWn8Uo4ykGJciCCfK2jjQbE_l4vqWeXgQGOupDg_BLvRehId7euODw5CR92_t_0NTzC6vvAzl3YXC1b_wbF18ruwYNMfNkLvvYbtMcsgg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lj9MwEIdHyyIBF96PwAIGceCSKontOpa4rBCrAu0e0K60FxTZjgMVVYqa5gB_PTPOgy0LCHFrmsnDiSf-2R5_A_CCW-lkPk3itKRpRhTUsUaZG6M4qQxXPjUJrXdeHE9np-LdmTzbg1fDWpiODzEOuJFnhO81OTgNSJ_zcrNaTWhSTV2Cy5TRO3SoPvyER6l-hAUVRCzQr3uuEMXxjIfutkYXJObFSMnzCjY0QUc34ONw813kyZdJu7UT9_0XruP_lu4mXO-1KTvsKtMt2PP1bbiy6Gff70AdaMhsScHtZUedZeuK0WB-u2UbgsD6ZtikHC2bT9-YCSVnFMLOwhKSBk_AKLOXL5mpS-ZM2-BVl8PKQ_yTOCm-uQunR29OXs_iPl9D7IRSKjbYGpY695x4kKn2HPumDhUer6zNvBCZQT2ZC2HzKjU-yaz1XvupVVNntBWc34P9el37B8BKl5VSGakISCdTpyuthU64xLNrk9sIXg7vrXA9zJxyaqyKoVODpSzC84vg-Wj6tSN4_M7oYHj5Re_ETUGgIJXrTKURPBt3o_vRnIqp_bpFGyWIqIMi-i82ORcZ6lKVRHC_q0_jnXBUhBIVQQT5Tk0bDQj_vbunXn4OGHCUhsTnl_gsQk36c-mKw_k8_Hj476ZP4ersZDEv5m-P3z-Ca3ipPs7zAPa3m9Y_Ri22tU-Cy_0AQUwvxg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Lb9QwEIdHpUgVF8qzBAoYxIFLVklsx7E4VZRVgW2FEJV6QIrsxIEVq2y12RzKX8-M86BLASFueUweTmbiX-zxZ4AX3MpCZmkUxiV1M6KgDjXK3BDFSWW4crGJaLzz8Ul6dCrencmzLXg1jIXp-BBjgxtFhv9eU4Cfl9WlIDeLxYT61NQ1uC7SKCOXPvz4kx2l-gYWFBChwLDusUKUxjMeulkZXVGYVxMlLwtYXwNNd-HzcO9d4sm3Sbu2k-L7L1jH_yzcLbjZK1N20LnSbdhy9R3YOe773u9C7VnIbE6p7WXHnGXLilFTfrtmK0LAumZYpRlaVl8umPEFZ5TAzvwAkgZPwGheL1cyU5esMG2DV50P4w5xI1FSXHMPTqdvPr0-CvvZGsJCKKVCg3VhqTPHiQYZa8fxz7RAfccraxMnRGJQTWZC2KyKjYsSa53TLrUqLYy2gvP7sF0va_cAWFkkpVRGKsLRybjQldZCR1zi2bXJbAAvh9eWFz3KnGbUWOTDLw2WMvfPL4Dno-l5x-_4ndH-8O7zPoSbnDBBKtOJigN4Nu7G4KMeFVO7ZYs2ShBPByX0X2wyLhJUpSoKYK9zp_FOOOpBiXoggGzD0UYDgn9v7qnnXz0EHIUh0fklPgvvSH8uXX4wm_mFh_9u-hR2PhxO89nbk_eP4AZeqU_y3Ift9ap1j1GIre0TH3A_ALRPLn4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+introduction+of+peanut+reduces+peanut+allergy+across+risk+groups+in+pooled+and+causal+inference+analyses&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Logan%2C+Kirsty&rft.au=Bahnson%2C+Henry+T.&rft.au=Ylescupidez%2C+Alyssa&rft.au=Beyer%2C+Kirsten&rft.date=2023-05-01&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=78&rft.issue=5&rft.spage=1307&rft.epage=1318&rft_id=info:doi/10.1111%2Fall.15597&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_all_15597
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon